eISSN: 1897-4309
ISSN: 1428-2526
Contemporary Oncology/Współczesna Onkologia
Current issue Archive Manuscripts accepted About the journal Supplements Addendum Special Issues Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
2/2021
vol. 25
 
Share:
Send email
Share:
abstract:
Original paper

Implementation of the enhanced recovery after surgery protocol for patients with peritoneal carcinomatosis undergoing cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion

Oleksandr Ivanovych Tkachenko
1
,
Sergii Hennadiiovych Chetverikov
1
,
Oleksandr Vadymovych Bondar
1
,
Viacheslav Yevheniiovych Maksymovskyi
1
,
Mykhailo Chetverikov
1
,
Valeriia Volodymyrivna Chetverikova-Ovchynnyk 
1

  1. Odessa National Medical University, Odessa, Ukraine
Contemp Oncol (Pozn) 2021; 25 (2): 133–139
DOI: https://doi.org/10.5114/wo.2021.107441
Online publish date: 2021/07/01
View full text Get citation
 
PlumX metrics:
Introduction
To investigate the feasibility of enhanced recovery after surgery (ERAS) protocol for patients with primary peritoneal carcinomatosis (PC) undergoing cytoreductive surgery with hyperthermic intraperitoneal chemoperfusion (HIPEC) based on the length of hospital stay (LOS), return of bowel function, the incidence of postoperative complications, and quality of life (QLQ) analysis.

Material and methods
The study included a total of 37 patients with primary PC of different origin, who underwent cytoreductive surgery plus HIPEC. Patients were divided into 2 groups: Group I (nonERAS) – 20 patients and Group II (ERAS) – 17 patients.

Results
The median LOS in Group I (nonERAS) (12.35 ± 3.9) was longer than in Group II (ERAS) (6.8 ± 1.9) (p < 0.01). The use of the ERAS protocol significantly contributed to the faster return of bowel function (peristalsis and stool) in the postoperative period (p < 0.01). There was no statistically significant difference in the incidence of postoperative complications between the ERAS and nonERAS groups, which supports its clinical safety. Improved QLQ according to the obtained data has also been achieved due to the introduction of the principles of the ERAS protocol.

Conclusions
The obtained results prove the expediency and feasibility of the implementation of the ERAS protocol among patients undergoing cytoreductive surgery in combination with HIPEC.

keywords:

peritoneal carcinomatosis, HIPEC, cytoreductive surgery, ERAS
FEATURED PRODUCTS
BOOKS
• Genetyka i leczenie chłoniaka rozlanego z dużych komórek B (DLBCL)
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.